Table 1 Study characteristics
All comparisons within studies (N = 164) | |
|---|---|
Primary analysis population as per author | |
ITT only | 42 (25.6%) |
PP only | 45 (27.4%) |
ITT and PP | 55 (33.5%) |
Not specified | 22 (13.4%) |
Sample size per group in the ITT population, Median (IQR) | 221.5 (129.5, 326.0) |
Proportion of treatment arm in the ITT population that was included in the PP population, Median (IQR) | 0.86 (0.79, 0.93) |
Proportion of control arm in the ITT population that was included in the PP population, Median (IQR) | 0.87 (0.77, 0.92) |
Definition of ITT | |
Based on assignment alone | 54 (32.9%) |
Use of drug at least once | 95 (57.9%) |
Other exclusion criteria used | 34 (20.7%) |
PP population clearly defined | 138 (84.2%) |
Definition of PP population | |
Exclusion based on concomitant therapy | 96 (58.5%) |
Exclusion based on incompliance | 123 (75.0%) |
Exclusion based on lost to follow-up | 118 (72.0%) |
Exclusion based on withdrawn from study due to other reasons | 29 (17.7%) |
Exclusion for other reasons | 28 (17.1%) |
Description of methods for handling missing data | 64 (39.0%) |
Missing data methods used | |
Missing data as failure | 58 (35.4%) |
Tipping point analysisa | 3 (1.8%) |
Multiple imputation | 4 (2.4%) |
Last outcome carried forward | 2 (1.2%) |
CI reported | |
2-sided 95% or 1-sided 97.5% CIb | 142 (86.6%) |